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STUDY QUESTION: Is there a difference in the odds of a live birth following blastocyst versus 19 
cleavage stage embryo transfer in the first complete cycle of IVF?  20 
SUMMARY ANSWER: After adjusting for indication bias, there was not enough evidence to 21 
suggest a difference in the odds of live birth following blastocyst versus cleavage stage 22 
embryo transfer in the first complete cycle of IVF. 23 
WHAT IS KNOWN ALREADY: Replacement of blastocyst stage embryos has become the 24 
dominant practice in IVF but there is uncertainty about whether this technique offers an 25 
improved chance of cumulative live birth over all fresh and frozen-thawed embryo transfer 26 









STUDY DESIGN, SIZE, DURATION: National population-based retrospective cohort study of 28 
100610 couples who began their first IVF/ICSI treatment at a licenced UK clinic between 1st 29 
January 1999 and 30th July 2010. 30 
PARTICIPANTS/MATERIALS, SETTING, METHODS: Data from the Human Fertilisation and 31 
Embryology Authority (HFEA) register on IVF/ICSI treatments using autologous gametes 32 
between 1999 and 2010 were analysed. The primary outcome was the live birth rate over 33 
the first complete cycle of IVF. Cumulative live birth rates (CLBR) were compared for couples 34 
who underwent blastocyst and cleavage transfer, and the adjusted odds of live birth over 35 
the first complete cycle were estimated for each group using binary logistic regression. This 36 
analysis was repeated within groups of female age, oocytes collected and primary versus 37 
secondary infertility. Inverse probability of treatment weighting was used to account for the 38 
imbalance in couple characteristics between treatment groups. 39 
MAIN RESULTS AND THE ROLE OF CHANCE: In total, 94294 (93.7%) couples had a cleavage 40 
stage embryo transfer while 6316 (6.3%) received blastocysts. Over the first complete cycle 41 
of IVF/ICSI (incorporating all fresh and frozen-thawed embryo transfers associated with the 42 









(56.5%) compared to cleavage stage embryo transfer (34.8%). However, after accounting for 44 
the imbalance between exposures, blastocyst transfer did not significantly influence the 45 
odds of live birth over the first complete cycle [adjusted odds ratio: 1.03 (0.96, 1.10)].  46 
LIMITATIONS, REASONS FOR CAUTION: Limitations of our study include the retrospective 47 
nature of the HFEA dataset and availability of linked data up until 2010. We were unable to 48 
adjust for some confounders, such as smoking status, BMI and embryo quality, as these data 49 
are not collected at national level by the HFEA. Similarly, there may be unknown couple, 50 
treatment or clinic variables that may influence our results. We were unable to assess the 51 
intended stage of embryo transfer for women who did not have an embryo replaced, and 52 
therefore excluded them from our study. Perinatal outcomes were not included in our 53 
analyses and would be a useful basis for future study. 54 
WIDER IMPLICATIONS OF THE FINDINGS: Our findings show that blastocyst stage embryo 55 
transfer may offer an improved chance of live birth in both the first fresh and the first 56 
complete cycle of IVF/ICSI compared to cleavage stage transfer, even in couples with 57 
typically poorer prognoses. Where possible, offering blastocyst transfer to a wider range of 58 
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In the UK, 1 in 6 couples experience infertility (Oakley et al., 2008), defined as the inability 78 
to conceive after 1 year of unprotected intercourse (Zegers-Hochschild et al., 2009).  The 79 
National Institute for Health and Care Excellence recommends IVF as the treatment of 80 
choice for prolonged unresolved infertility irrespective of cause (Human Fertilisation and 81 
Embryology Authority, 2018). Over 1 million treatments have been offered between 1991 82 
and 2016 in the UK (Human Fertilisation and Embryology Authority, 2018). 83 
In the 40 years since the inception of IVF, there have been continuous advances in ART. The 84 
focus on increasing live birth rates whilst reducing the time taken to achieve pregnancy has 85 
led to the use of techniques such as extended embryo culture until blastocyst stage (day 86 









(Human Fertilisation and Embryology Authority, 2016). Meta-analyses of randomised trials 88 
have demonstrated an increased live birth rate after fresh blastocyst transfer in comparison 89 
with fresh cleavage stage transfer (Glujovsky et al., 2016, Wang, S. and Sun, 2014) and 90 
suggested a potential reduction in the risk of first-trimester miscarriage (Wang and Sun, 91 
2014).  92 
Simultaneously, growing awareness of the risks of multiple pregnancy and developments in 93 
embryo freeze-thaw methods have led to a move to replace fewer embryos and 94 
cryopreserve any surplus for future use (Human Fertilisation and Embryology Authority, 95 
2018). However, it is unknown whether an embryo transfer strategy that optimises success 96 
rates following a fresh embryo transfer would be equally effective in the context of 97 
subsequent frozen-thawed embryo transfers. Therefore, it has become essential that the 98 
immediate gains associated with fresh blastocyst transfer be assessed against the potential 99 
risk of having fewer blastocysts to transfer after freezing and thawing – especially in women 100 
with fewer embryos. A Cochrane review (Glujovsky et al., 2016) has suggested that 101 
cumulative live birth rates (CLBR) are sustained following blastocyst transfer, but as relevant 102 









study to determine whether blastocyst stage embryo transfer is associated with a higher 104 
chance of cumulative live birth (i.e. fresh followed by frozen embryo transfers arising from a 105 
single oocyte retrieval episode) in comparison with cleavage stage embryo transfer. We also 106 
investigated whether the association varies in different subgroups of women based on age, 107 
number of oocytes collected and history of previous pregnancy. 108 
Materials and Methods 109 
The Human Fertilisation and Embryology Authority (HFEA) routinely collects information 110 
submitted by all licenced UK fertility clinics about their patients, treatments and outcomes. 111 
Access to a linked form of the register allows tracking of women through fresh and frozen 112 
treatments and calculation of CLBR (McLernon et al., 2016, McLernon et al., 2016). Approval 113 
to access linked HFEA data was given by the North of Scotland Research Ethics Committee, 114 









Study population  116 
In this population-based cohort study anonymised linked data were extracted from the 117 
HFEA database for all IVF/ICSI patients who began their first ovarian stimulation treatment 118 
at a licenced UK clinic between 1st January 1999 and 30th July 2010.  Records of any 119 
associated frozen cycles carried out before 30th July 2011 were also included to give women 120 
time to complete any frozen transfers that were associated with their first complete cycle of 121 
treatment. As all treatment data were linked to the individual women who received them, it 122 
was possible to code their initial fresh treatment and any associated frozen treatments as 123 
their first complete cycle on a per-woman basis (McLernon et al., 2016). We defined a 124 
complete cycle as all fresh and frozen-thawed embryo transfer attempts associated with a 125 
single oocyte retrieval episode (Moragianni and Penzias, 2010).  126 
Consent for IVF patient data to be used in research changed from ‘presumed’ to ‘required’ 127 
in October 2009.  Therefore, from October 2009, only details relating to those patients who 128 
provided explicit consent for their data to be used in research were available. To determine 129 









characteristics of patients who started their first cycle of IVF between 1st January 2008 and 131 
30th September 2009, and between 1st October 2009 and 30th June 2010.  132 
Exposure groups 133 
After exclusion criteria were applied (Fig. 1), women were divided into two comparison 134 
groups based on the stage of embryo used in their first fresh transfer, i.e., blastocyst (day 135 
5/6) or cleavage (day 2/3). 136 
Baseline characteristics 137 
We assessed baseline characteristics for all women at the beginning of their first cycle of 138 
treatment (i.e. their first oocyte retrieval and subsequent fresh embryo transfer). This 139 
included: age; duration of infertility (years); previous history of pregnancy (i.e. primary or 140 
secondary infertility); type of infertility (unexplained, endometriosis, tubal, anovulatory, 141 
male factor or multiple diagnoses). With regards to treatment, we assessed: type of 142 
treatment used (IVF/ICSI); number of oocytes retrieved; number of embryos transferred; 143 










The primary outcome in this study was the live birth rate over the first complete cycle of 146 
IVF. 147 
Ethical approval 148 
Ethical approval was granted by the North of Scotland Research Ethics Committee 149 
(12/NS/0119). The study sponsor, Research Governance, University of Aberdeen, granted a 150 
non-substantial ethical amendment on 4th Oct 2017. 151 
Missing data 152 
A total of 27957 (27.8%) women had at least one variable with missing data. Multiple 153 
imputation of missing data was performed to increase the power of the study by allowing us 154 
to include women who would have been excluded otherwise. This procedure assumes that 155 
missing data were missing at random, conditional on the observed covariates and outcome. 156 
Missing values were imputed based on other covariates measured at the first treatment. 157 









treatment; category of infertility (tubal, anovulatory, male factor, endometriosis or 159 
unexplained); and duration of infertility. Treatment related characteristics included: number 160 
of oocytes retrieved; treatment used (ICSI/IVF); number of embryos created; number of 161 
embryos transferred; live birth status following the first fresh embryo transfer; whether any 162 
embryos were cryopreserved; and the stage of any embryos transferred 163 
(blastocyst/cleavage). In order to check that the covariates used for the multiple imputation 164 
were plausible predictors of missingness, a multivariable logistic regression was used to 165 
predict if any missing data was present. Any covariates showing a statistically significant 166 
association with missing data would support our assumption that the data were missing at 167 
random (Curran et al., 1998). Ten imputed datasets were created. 168 
Inverse probability of treatment weighting 169 
To address the effect of confounding by indication in our analyses, inverse probability of 170 
treatment weighting (IPTW) was used. After weighting each subject by the inverse of their 171 
propensity score (i.e. the probability of receiving blastocyst embryo transfer over cleavage 172 
embryo transfer), the distribution of baseline characteristics should be approximately equal 173 









For each of the 10 imputed datasets, a generalised linear mixed model was used to generate 175 
the predicted probability of receiving a blastocyst transfer for each patient. Covariates 176 
included factors that could have influenced the decision to opt for a blastocyst transfer, 177 
based on previous research (Marsh et al., 2012), and other observed characteristics of 178 
treatment to improve the fit of the model. These are listed in the baseline characteristics 179 
section described earlier. Additionally, the IVF clinic where the treatment was performed 180 
was included in the model as a random intercept as some clinics may not have performed 181 
blastocyst transfers during the study period. The inverse of the predicted probability of 182 
having a blastocyst stage embryo transfer was used as a weighting variable for each patient.  183 
Women who underwent blastocyst transfer had their data weighted by the inverse 184 
probability of having a blastocyst transfer:  185 
                                           
                                            
 
Women who underwent cleavage stage transfer had their data weighted by the inverse 186 









                                               
                                              
 
The decision was taken to truncate the weights of all cases to the 0.1st and 99.9th percentile, 188 
to prevent very large or very small weights affecting the variance of our estimates (Austin 189 
and Stuart, 2015). Balance diagnostics were performed to test whether IPTW was effective 190 
in balancing baseline characteristics between women who had cleavage stage transfer and 191 
those who had blastocyst transfer (Austin and Stuart, 2015). Further information on the 192 
IPTW process and results can be found in the Supplementary Data. 193 
Association between blastocyst versus cleavage stage transfer and cumulative 194 
live birth 195 
A logistic regression model was fitted with IPTW to assess the influence of stage of transfer 196 
(blastocyst versus cleavage) on the odds of live birth over the first complete cycle of IVF. 197 
This model was then fitted in each of the 10 imputed datasets with the treatment weights 198 
applied. The 10 sets of odds ratios were pooled to give the final adjusted odds ratio (AOR) 199 









weighting the model given that women with larger weights contribute more heavily to the 201 
model than those with smaller weights. This allowed assessment of the effect of using 202 
blastocyst compared with cleavage stage transfer on the odds of live birth, adjusted for 203 
confounding by indication. 204 
Subgroup analyses 205 
In order to understand if certain subpopulations had increased odds of live birth following 206 
transfer of a blastocyst rather than a cleavage stage embryo, we performed analyses split by 207 
certain characteristics. These included age groups (<31, 31-35, 36-40, >40 years), previous 208 
history of pregnancy (primary or secondary infertility) and number of oocytes collected (1-7, 209 
8-15, >15). 210 
For each subgroup, we generated new inverse probability of treatment weights within each 211 
imputed dataset. We then used these to weight a logistic regression model to assess the 212 









Sensitivity analyses 214 
Complete case analysis 215 
The logistic regression model for live birth was fitted only to patients with complete data to 216 
determine whether any bias may have been introduced by not imputing the missing data.  217 
IBM SPSS Statistics for Windows, Version 25.0 was used for all statistical analyses (IBM Corp. 218 
Armonk, NY). 219 
Results 220 
Baseline characteristics 221 
The baseline characteristics (before multiple imputation) of all couples at the start of their 222 
first complete cycle of IVF or ICSI are shown in Table I.  A total of 94294 (93.7%) couples had 223 
a cleavage stage embryo transfer while 6316 (6.3%) received blastocyst embryo transfer 224 
(Fig. 1). The number of blastocyst transfer episodes increased throughout the study, from 71 225 









female age was similar between the two exposure groups, as well as the proportions of the 227 
different causes of infertility. Duration of infertility tended to be 1 year shorter on average 228 
for those in the blastocyst group, with a median of 3 (interquartile range (IQR) 2-5) years of 229 
trying to conceive compared to 4 (IQR 3-6) in the cleavage group. Those in the blastocyst 230 
group also tended to have a higher number of oocytes collected, with a median of 14 (IQR 231 
10-18) compared to 9 (IQR 6-13) in those who had cleavage stage transfer.  232 
Couples who had blastocyst stage transfer were more likely to use ICSI, making up 53.6% of 233 
treatments compared to 45.8% in those who had a cleavage stage transfer. Double embryo 234 
transfer was more commonly used than single embryo transfer in both groups, at 87.8% and 235 
70.3% in the cleavage and blastocyst groups, respectively. The proportion of single embryo 236 
transfers was 12.2% in the cleavage group, while for those who had blastocyst stage 237 
transfer this was more than double at 29.7%. Almost half of the couples who underwent 238 
blastocyst stage transfer were able to freeze some embryos (47.4%) compared to only one- 239 
third of couples who had cleavage stage transfers. 240 
The only differences observed between the characteristics of women who started treatment 241 









(when the opt-in policy for consent to use IVF data for research purposes was introduced) 243 
were related to treatment (Supplementary Table SI). More women had single and blastocyst 244 
stage embryo transfers during the latter period. These differences reflect the change in IVF 245 
practice rather than any difference in the characteristics of the women. 246 
Live birth rates 247 
Blastocyst stage embryo transfer was associated with a higher CLBR compared to cleavage 248 
stage embryo transfer, at 56.48% (55.25, 57.70) and 34.79% (34.49, 35.10) respectively.   249 
After accounting for the imbalance in baseline characteristics between the two exposure 250 
groups, women who had blastocyst stage embryo transfer did not have significantly 251 
increased odds of having a baby over the first complete cycle compared to women who had 252 
a cleavage stage embryo transfer (Table II) [AOR: 1.03 (0.96, 1.10)]. 253 
Subgroup analyses 254 









Table II shows the results of the subgroup analyses, including live birth rates and the 256 
weighted odds of live birth for blastocyst versus cleavage stage embryo transfer. The use of 257 
blastocyst stage embryo transfer gave significantly higher odds of live birth compared to 258 
cleavage stage embryo transfer in women under 31 years old, but not in any other age 259 
groups. In these women under 31 years old, women who had blastocyst transfer were 260 
almost 20% more likely to have a live birth than those who had a cleavage stage transfer 261 
[AOR: 1.19 (1.05, 1.35)]. 262 
Primary versus secondary infertility 263 
For couples with no previous pregnancies, those who underwent blastocyst transfer had 264 
slightly higher odds of live birth than those who had cleavage stage transfer [AOR: 1.10 265 
(1.00, 1.21)] (Table II). However, stage of embryo transfer did not have a significant effect 266 
on the chance of live birth in couples who had a history of secondary infertility [AOR: 0.87 267 
(0.71, 1.06)]. 268 









Blastocyst transfer had a varying effect on the odds of live birth when compared against 270 
cleavage stage transfer across the three categories of number of oocytes retrieved. It made 271 
no significant difference to the odds of live birth for women with 1-7 eggs collected [AOR: 272 
1.14 (0.95, 1.36)]. However, for women with 8-15 eggs collected, the use of blastocyst 273 
transfer over cleavage stage transfer gave them a statistically significant 14% increase in the 274 
odds of live birth [AOR: 1.14 (1.05, 1.24)]. 275 
In contrast to the effect seen in the observed live birth rate, women with more than 15 eggs 276 
collected at the start of their cycle were significantly more likely to have a live birth with a 277 
cleavage stage transfer. Following the use of treatment weighting, blastocyst transfer 278 
reduced their odds of live birth by over one-fifth [AOR: 0.79 (0.69, 0.91)]. 279 
Sensitivity analysis 280 
Complete cases only analysis 281 
The odds of having missing data were higher for women whose IVF treatment occurred in 282 









had a blastocyst (versus cleavage) stage embryo transfer (Supplementary Table SII). When 284 
the weighted logistic regression model was fitted to women who only had complete data, 285 
blastocyst transfer was a significant negative predictor for live birth [OR: 0.86 (0.77, 0.97)]. 286 
This reflects the biased results associated with excluding women with missing data.  287 
Discussion 288 
Principal findings 289 
Our results show that blastocyst stage embryo transfer does not significantly influence the 290 
odds of cumulative live birth in the first complete cycle of IVF/ICSI incorporating the transfer 291 
of frozen embryos accruing from a single oocyte retrieval. Certain subgroups may benefit 292 
from the use of blastocyst transfer over cleavage stage transfer, such as younger women 293 
and those with no history of previous pregnancy.  294 
Strengths and limitations 295 
We used national data to estimate the chance of live birth following blastocyst versus 296 









blastocyst and cleavage stage transfer in individual fresh or frozen cycles (Wang, Y. A. et al., 298 
2010), our study was able to link embryo transfer episodes together to give a clear picture 299 
of the chance of success over a complete cycle of IVF/ICSI. The use of national linked data 300 
gives our study increased power and generalisability to expand upon the findings of smaller 301 
single-site studies that have estimated CLBRs for blastocyst and cleavage stage transfers (De 302 
Vos et al., 2016, Goldman et al., 2016, Yin et al., 2017).  303 
Many previously published observational studies do not account for the effect of 304 
confounding by indication. Given that blastocyst transfer tends to be more commonly used 305 
in patients with better prognostic profiles (Marsh et al., 2012), this may introduce bias into 306 
results if not adjusted for in analyses. Yin et al. used propensity-score matching to ensure 307 
equal distribution of key variables in both groups. However, this necessitates the exclusion 308 
of participants who do not match from the dataset (Yin et al., 2017). This reduces the 309 
sample size, thereby diminishing the power and generalisability of subsequent analyses 310 
(Austin, 2011). To retain the full population for comparison, our study adjusted for 311 
confounding by indication using IPTW (Austin, 2011, Austin and Stuart, 2015). In addition to 312 









technique reduced the risk of introducing bias through patient selection and increased the 314 
power of our study compared to the alternative propensity score matching method.  315 
The fact that women with single and blastocyst embryo transfers and whose treatment 316 
occurred during the latter years of the study were more likely to have missing data, suggests 317 
that our assumption that the data were missing at random (i.e. difference between missing 318 
and observed values can be explained by differences in observed data) and therefore our 319 
approach of multiple imputation was reasonable.  320 
However, limitations of our study include the retrospective nature of the HFEA dataset and 321 
availability of linked data up until 2010. Any information not collected in the dataset could 322 
not be assessed, and therefore useful indicators for success, such as BMI, smoking, embryo 323 
quality, embryo freezing method and surplus embryos, were not included in analyses 324 
(Glujovsky et al., 2016). These indicators would be important to include in future 325 
randomised controlled trials (RCTs) to further elucidate their influence on the outcomes of 326 
blastocyst and cleavage stage transfers. We included cryopreservation of embryos after the 327 
first fresh transfer as a proxy for quality, assuming that if few high-quality embryos were 328 









There were no variables included in the HFEA dataset to validate our exposure variable 330 
(blastocyst versus cleavage stage embryo transfer). We constructed this variable using the 331 
time from egg retrieval to embryo transfer, and therefore we cannot rule out the influence 332 
of measurement error due to errors in data recording. On 1st October 2009 the HFEA policy 333 
for couples to give consent for their data to be used for research purposes changed from 334 
opt-out to opt-in. This meant that the treatment cycles of couples who did not give explicit 335 
consent after this point were not available for research. Since 2009 blastocyst transfers have 336 
increased in popularity. Therefore, we cannot rule out that improvements in IVF practice 337 
over the past 10 years would lead to a different effect size for blastocyst versus cleavage 338 
transfer. However, a recent systematic review and meta-analysis, which included trials as 339 
recent as 2015, showed a broadly similar effect size to ours (Risk Ratio=1.11 (95% CI 0.92 to 340 
1.35)) (Martins et al, 2017). 341 
Additionally, the developmental stage (blastocyst/cleavage) of embryos transferred in 342 
frozen cycles was not available, and so we assumed that the majority of women would 343 
cryopreserve embryos at the same stage as the first fresh transfer. Unfortunately, this does 344 









kept others in culture until blastocyst stage for their first fresh transfer. Previous work in a 346 
similar national database has shown that only 1.3% of couples opted to do this, so this is 347 
unlikely to majorly impact our findings (Wang et al., 2010). We were unable to assess the 348 
intended stage of embryo transfer for women who did not have an embryo replaced, and 349 
therefore had to exclude them from our study. This introduces bias, as it allows us to 350 
comment only on actual blastocyst transfer as an exposure, rather than the decision to 351 
undertake blastocyst transfer, which is the reality faced by clinicians and patients. It remains 352 
unknown whether a characteristic of each clinic, patient or cycle may have caused 353 
participants to transfer at cleavage stage as opposed to blastocyst stage. For example, by 354 
the end of the study period in 2010, many clinics were simply unable to offer blastocyst 355 
transfer if their embryology labs were not yet prepared for it. Given that it has previously 356 
been shown that failure to transfer is higher in women who use extended culture to 357 
blastocyst stage (Glujovsky et al., 2016), there is still a need for the outcomes of these 358 









Findings in relation to existing literature 360 
A recent Cochrane review suggested that blastocyst transfer improves clinical pregnancy 361 
rates in fresh cycles but not in complete IVF cycles incorporating fresh and frozen embryo 362 
transfers (Glujovsky et al., 2016). Although our study found a higher CLBR following 363 
blastocyst transfer compared to cleavage stage transfer, after we adjusted for indication 364 
bias using IPTW this association disappeared. This brings our findings into line with those of 365 
previous retrospective cohort studies, which found no difference in CLBRs after comparing 366 
blastocyst with cleavage stage transfer (De Vos et al., 2016, Yin et al., 2017). We have 367 
shown a higher rate of cryopreservation in couples who underwent blastocyst transfer. 368 
Whilst this is in contrast to two previous studies, (De Vos et al., 2016, Glujovsky et al., 2016), 369 
one other study that shared our finding reported that frozen-thawed blastocyst transfer 370 
showed a significantly higher live birth rate compared to frozen-thawed cleavage stage 371 
embryo transfers after matching on propensity score. However, again, significance was not 372 
maintained when cumulative rates were considered (Yin et al., 2017). 373 
A major change in UK clinical practice over the time period of this study has been the 374 









compared to slow-freezing (Raju et al., 2005, Takahashi et al., 2005). In the 2016 Cochrane 376 
review by Glujovsky et al., a single trial, which used vitrification, was the only one (out of 377 
the five included trials that provided cumulative pregnancy rates) to show that blastocyst 378 
transfer resulted in higher odds of cumulative pregnancy (n=120, OR: 2.44 [1.17, 5.12]) 379 
(Glujovsky et al., 2016). 380 
Our study stands out amongst previous retrospective cohort studies in this area due to the 381 
originality of our subgroup findings. To our knowledge, previous research has focussed on 382 
comparisons of overall outcome rates between blastocyst and cleavage stage embryo 383 
transfer and lack the statistical power of national linked data to investigate the association 384 
within subgroups (De Vos et al., 2016, Yin et al., 2017). Among RCTs, the Cochrane review by 385 
Glujovsky et al. presented meta-analyses for cumulative pregnancy rates in subgroups such 386 
as poor versus good prognosis. Their results emphasised that couples with “good” 387 
prognostic factors (i.e. couples with characteristics favourable for natural conception) had 388 
an increased chance of pregnancy over the first complete cycle if cleavage stage transfer 389 
was used compared to blastocyst transfer (Glujovsky et al., 2016).  Our study, however, 390 









associated with good prognosis (female age <31 years, primary infertility, 8-15 eggs 392 
retrieved) blastocyst transfer resulted in improved odds of live birth over the first complete 393 
cycle of IVF/ICSI. When the influence of indication bias is removed, there is no “one size fits 394 
all” transfer policy. We have identified key subgroups who may benefit from one type of 395 
embryo transfer over the other, and future meta-analyses could seek to elucidate this 396 
further. 397 
Implications for clinical practice 398 
Blastocyst transfer has established itself as the favoured option for couples and clinicians 399 
wishing to optimise live birth chances following the first embryo transfer episode. However, 400 
until recently there was very little research to indicate whether this perception holds true 401 
over a complete cycle of IVF. Patients and clinicians choose to opt for extended culture 402 
based on uncertain outcomes, at the risk of few embryos surviving and decreasing the 403 
number of pregnancy opportunities available to them. After accounting for the imbalance 404 
between the exposures, our results show that blastocyst transfer does not significantly 405 
increase the odds of having a baby over the first complete cycle. This knowledge will aid 406 









cleavage stage embryo transfer offers the best chance of success over a full cycle of IVF, 408 
rather than just the first step. 409 
There is a perception that blastocyst transfer is most suitable for couples with a good 410 
prognosis, and in our dataset blastocyst transfers were much more common in high-411 
responders with a high number of oocytes and a history of previous pregnancy. This profile 412 
has also been observed by Marsh et al. in the USA (Marsh et al., 2012). However, our results 413 
indicate this assumption may not be entirely accurate. Couples with primary infertility were 414 
significantly more likely than couples with secondary infertility to have a live birth following 415 
blastocyst transfer compared to cleavage stage transfer. Additionally, while couples with 8-416 
15 eggs retrieved had significantly increased odds of live birth following blastocyst transfer, 417 
high-responders with more than 15 eggs collected showed the opposite, and were more 418 
likely to succeed with cleavage stage transfer. 419 
Our results indicate that while certain subgroups exist who may benefit from blastocyst 420 
transfer, routine use of blastocyst transfer may not increase the odds of cumulative live 421 
birth in the overall UK population. This can be used to help advise couples undergoing 422 









At the same time, before any strong recommendations can be made it is worth keeping in 424 
mind that any potential impact of blastocyst transfer on the future health of the offspring 425 
has yet to be fully elucidated. Previous studies have indicated that blastocyst transfer may 426 
be associated with increased birthweight and sex selection (with increased odds of have a 427 
male baby) (Chang et al., 2009, Kaartinen et al., 2015). A systematic review of observational 428 
data which was unable to adjust for confounders has suggested that babies conceived from 429 
replaced blastocysts may be at a higher risk of very preterm delivery (Maheshwari et al., 430 
2013). There may be unforeseen consequences of extended culture and embryo selection 431 
that should be further investigated ahead of any changes to clinical practice. 432 
Implications for research 433 
To further inform patients about the viability of blastocyst transfer, the effect of potentially 434 
important confounders, such as vitrification and embryo quality, on the relationship 435 
between stage of embryo transfer and live birth should be explored in large RCTs to elicit 436 
CLBRs (Fleischer et al., 2018, Glujovsky et al., 2016). Couples and policymakers may be 437 
primarily concerned with the chance of leaving treatment with a live baby, but it is our 438 









“healthy” baby. Given that concerns have previously been raised regarding the perinatal 440 
outcomes of blastocyst transfer (Alviggi et al., 2017, Chang et al., 2009, Kaartinen et al., 441 
2015, Maheshwari et al., 2013), future population-level studies in linked datasets with more 442 
current data and RCTs should endeavour to report these outcomes alongside pregnancy and 443 
live birth rates. 444 
Conclusions 445 
Blastocyst transfer does not influence the chance of live birth in the first complete cycle of 446 
IVF/ICSI in comparison with cleavage stage transfer, but may show improved odds of live 447 
birth in particular patient subgroups (i.e. couples with no previous pregnancies, those with 448 
8-15 eggs collected, and where the female partner is younger than 31 years). Routine use of 449 
blastocyst transfer may increase cumulative success rates for such couples, but robust data 450 
on offspring outcomes should be considered before any firm recommendations can be 451 
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Figure legends 483 
Figure 1 Flow chart of exclusion criteria in a study of cumulative live birth rates following 484 









Supplementary figures 486 
Supplementary Figure S1 Log-transformation of duration of infertility before imputation of 487 
missing data prevented normalisation of the skewed distribution of the variable. 488 
 (A) Distribution of duration of infertility without log-transformation in complete and 489 
imputed cases (B) Distribution of duration of infertility after log-transformation in complete 490 
and imputed cases. 491 
Supplementary Figure S2 Standardised difference in the mean of continuous variables and 492 
proportion of dichotomous variables between blastocyst and cleavage stage transfer, before 493 
and after inverse probability of treatment weighting.  494 
Weighting lowered the standardised difference between the two comparison groups, 495 











Alviggi C, Conforti A, Carbone IF, Borrelli R, de Placido G, Guerriero S. Influence of 499 
cryopreservation on perinatal outcome after blastocyst- vs cleavage-stage embryo transfer: 500 
systematic review and meta-analysis. Ultrasound Obstet Gynecol 2017;51:54-63. 501 
Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of 502 
Confounding in Observational Studies. Multivariate Behav Res 2011;46:399-424. 503 
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of 504 
treatment weighting (IPTW) using the propensity score to estimate causal treatment effects 505 
in observational studies. Stat Med 2015;34:3661-3679. 506 
Chang HJ, Lee JR, Jee BC, Suh CS, Kim SH. Impact of blastocyst transfer on offspring sex ratio 507 
and the monozygotic twinning rate: a systematic review and meta-analysis. Fertil Steril 508 
2009;91:2381-2390. 509 
Curran D, Bacchi M, Schmitz SFH, Molenberghs G, Sylvester RJ. Identifying the types of 510 









De Vos A, Van Landuyt L, Santos-Ribeiro S, Camus M, Van dV, Tournaye H, Verheyen G. 512 
Cumulative live birth rates after fresh and vitrified cleavage-stage versus blastocyst-stage 513 
embryo transfer in the first treatment cycle. Hum Reprod 2016;31:2442-2449. 514 
Fleischer K, Cornelisse S, Mastenbroek S, Repping S. An informed decision between 515 
cleavage-stage and blastocyst-stage transfer in IVF requires data on the transfers of frozen–516 
thawed embryos. Hum Reprod 2018;33:1370. 517 
Glujovsky D, Farquhar C, Quinteiro Retamar AM, Alvarez Sedo CR, Blake D. Cleavage stage 518 
versus blastocyst stage embryo transfer in assisted reproductive technology. Cochrane 519 
Database of Systematic Reviews 2016. 520 
Goldman RH, Kaser DJ, Missmer SA, Srouji SS, Farland LV, Racowsky C. Building a model to 521 
increase live birth rate through patient-specific optimization of embryo transfer day. J Assist 522 
Reprod Genet 2016;33:1525-1532. 523 
Human Fertilisation and Embryology Authority. Fertility Treatment 2014-2016: Trends and 524 










Human Fertilisation and Embryology Authority. Fertility Treatment 2014: Trends and 527 
Figures. 2016. https://www.hfea.gov.uk/media/1783/fertility-treatment-2014-trends-and-528 
figures.pdf. 529 
Kaartinen NM, Kananen KM, Rodriguez-Wallberg KA, Tomas CM, Huhtala HS, Tinkanen HI. 530 
Male gender explains increased birthweight in children born after transfer of blastocysts. 531 
Hum Reprod 2015;30:2312-2320. 532 
Maheshwari A, Kalampokas T, Davidson J, Bhattacharya S. Obstetric and perinatal outcomes 533 
in singleton pregnancies resulting from the transfer of blastocyst-stage versus cleavage-534 
stage embryos generated through in vitro fertilization treatment: a systematic review and 535 
meta-analysis. Fertil Steril 2013;100:1615-1621. 536 
Marsh CA, Farr SL, Chang J, Kissin DM, Grainger DA, Posner SF, Macaluso M, Jamieson DJ. 537 
Trends and factors associated with the Day 5 embryo transfer, assisted reproductive 538 









Martins WP, Nastri CO, Rienzi L, van der Poel SZ, Gracia C, Racowsky C. Blastocyst vs 540 
cleavage-stage embryo transfer: systematic review and meta-analysis of reproductive 541 
outcomes. Ultrasound Obstet Gynecol 2017;49:583-91. 542 
McLernon DJ, Maheshwari A, Lee AJ, Bhattacharya S. Cumulative live birth rates after one or 543 
more complete cycles of IVF: a population-based study of linked cycle data from 178 898 544 
women. Hum Reprod 2016;31:572-581. 545 
McLernon DJ, Steyerberg EW, Te Velde ER, Lee AJ, Bhattacharya S. Predicting the chances of 546 
a live birth after one or more complete cycles of in vitro fertilisation: Population based study 547 
of linked cycle data from 113 873 women. BMJ 2016;355. 548 
Moragianni VA, Penzias AS. Cumulative live-birth rates after assisted reproductive 549 
technology. Curr Opin Obstet Gynecol 2010;22:189-192. 550 
Oakley L, Doyle P, Maconochie N. Lifetime prevalence of infertility and infertility treatment 551 










Raju GAR, Haranath GB, Krishna KM, Prakash GJ, Madan K. Vitrification of human 8-cell 554 
embryos, a modified protocol for better pregnancy rates. Reprod BioMed Online 555 
2005;11:434-437. 556 
Takahashi K, Mukaida T, Goto T, Oka C. Perinatal outcome of blastocyst transfer with 557 
vitrification using cryoloop: A 4-year follow-up study. Fertil Steril 2005;84:88-92. 558 
Wang S, Sun H. Blastocyst Transfer Ameliorates Live Birth Rate Compared with Cleavage-559 
Stage Embryos Transfer in Fresh In Vitro Fertilization or Intracytoplasmic Sperm Injection 560 
Cycles: Reviews and Meta-Analysis. Yonsei Med J 2014;55:815-825. 561 
Wang YA, Chapman M, Costello M, Sullivan EA. Better perinatal outcomes following transfer 562 
of fresh blastocysts and blastocysts cultured from thawed cleavage embryos: a population-563 
based study. Hum Reprod 2010;25:1536-1542. 564 
Yin Y, Chen G, Li K, Liao Q, Zhang S, Ma N, Chen J, Zhang Y, Ai J. Propensity score-matched 565 
study and meta-analysis of cumulative outcomes of day 2/3 versus day 5/6 embryo 566 









Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K, Sullivan 568 
E, Vanderpoel S. International Committee for Monitoring Assisted Reproductive Technology 569 
(ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 570 





















STAGE OF EMBRYO TRANSFERRED AT FIRST FRESH CYCLE,  
n (%) unless otherwise stated 
CLEAVAGE (n = 94294) BLASTOCYST (n = 6316) 
Age (year), mean (SD) 33.7 (4.5) 33.7 (4.4) 
Duration of infertility (years), 
median (IQR) 
4 (3-6) 3 (2-5) 
 Missing 22818 (24.2) 3598 (57.0) 
Type of infertility   
 Primary infertility 55180 (58.5) 1798 (28.5) 
 Secondary infertility 20143 (21.4) 994 (15.7) 
 Missing 18971 (20.1) 3524 (55.8) 
Cause of infertility   
 >1 cause 12534 (13.3) 990 (15.7) 
 Tubal 15701 (16.7) 823 (13.0) 
 Anovulatory 6249 (6.6) 484 (7.7) 
 Male factor 32222 (34.2) 2129 (33.7) 
 Endometriosis 3561 (3.8) 184 (2.9) 
 Unexplained 24027 (25.5) 1706 (27.0) 
Year of first oocyte retrieval   
 1999-2001 17565 (18.6) 71 (1.1) 
 2002-2004 26929 (28.6) 708 (11.2) 
 2005-2007 30829 (32.7) 2013 (31.9) 
 2008-2010 18971 (20.1) 3524 (55.8) 
Type of treatment   
                IVF 51126 (54.2) 2932 (46.4) 
                ICSI 43168 (45.8) 3384 (53.6) 
Oocytes retrieved, median (IQR) 9 (6-13) 14 (10-18) 
Embryos transferred   
 1 11541 (12.2) 1875 (29.7) 
 2 82753 (87.8) 4441 (70.3) 
Embryos frozen   
 Yes 27627 (29.3) 2995 (47.4) 

























NUMBER OF LIVE BIRTHS/NUMBER 
OF BLASTOCYST STAGE EMBRYO 
TRANSFERS (%) 
NUMBER OF LIVE BIRTHS/ 
NUMBER OF CLEAVAGE STAGE 
EMBRYO TRANSFERS (%) 
WEIGHTED ODDS RATIO 
(95% CI) FOR BLASTOCYST 
VERSUS CLEAVAGE 
All women undergoing IVF/ICSI 3567/6316 (56.5) 32809/94294 (34.8) 1.03 (0.96, 1.10) 
Subgroups    
Age groups (years)    
 <31 922/1519 (60.7) 9243/22196 (41.6) 1.19 (1.05, 1.35) 
 31-35 1572/2523 (62.3) 15017/37927 (39.6) 0.97 (0.87, 1.08) 
 36-40 989/1954 (50.6) 8155/29190 (27.9) 0.95 (0.82, 1.11) 
 >40 84/320 (26.3) 394/4981 (7.9) 1.52 (0.70, 3.28) 
Type of infertility    
 Primary infertility 2252/3975 (56.7) 23762/68468 (34.7) 1.10 (1.00, 1.21) 
 Secondary infertility 1315/2341 (56.2) 9047/25826 (35.0) 0.87 (0.71, 1.06) 
Number of oocytes retrieved    
 1-7 262/585 (44.8) 9347/36936 (25.3) 1.14 (0.95, 1.36) 
 8-15 1823/3313 (55.0) 16752/42705 (39.2) 1.14 (1.05, 1.24) 













Initial population  
 
218,591 women (aged 18-50 years old) with 388,552 complete cycles of IVF/ICSI (438,454 
fresh/frozen treatments) between 1992 and 2011 
 
253,417 women with 464,333 cycles (564,224 fresh/frozen treatments) 
Exclusions 
Women whose first cycle started before 1999 (71551 women) 
Women with cervical diagnosis (99 women) 
Cycles that commenced after 1st July 2010 (keeping frozen 
treatments related to cycles that commenced 1st July 2010) 
(10613 women) 
Treatments occurring after the first live birth (4363 cycles) 
Women with no recorded type of infertility (5667 women) 
Women with no embryos frozen yet had records of frozen 
embryo transfers (158 women) 
Women with 0 or >2 embryos transferred (26910 women) 
Women with embryo transfer on day 0, 1 or 4 (1634 women) 
Women with missing date of embryo mixing or transfer (1342 
women) 
Women with no oocytes collected (7 women) 
 
Study population 
100610 women with 112,713 fresh or frozen embryo transfer attempts in the first complete cycle, 
from 1st Jan 1999 to 30th June 2010 
Blastocyst stage embryo transfer 
N=6,316 (6.3%) 
Cleavage stage embryo transfer 
N=94,294 (93.7%) 
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